Beyond CRISPR: The New Generation of Genome Editors
Emerging tools promise to overcome CRISPR's limitations for large-scale DNA modifications.
1CRISPR's limitations exposed
While CRISPR-Cas9 revolutionized gene editing by enabling precise DNA cuts, researchers like Ying Zhang at Wuhan University found it inadequate for replacing entire faulty genes. The technique's reliance on error-prone cellular repair mechanisms often produces unpredictable results. For diseases like Stargardt's vision loss with over 1,200 genetic variants, CRISPR's piecemeal approach would require hundreds of distinct therapies - an impractical solution for comprehensive treatment.
2Base editing's precision problem
Though more precise than standard CRISPR, base editing faces its own constraints. Each therapy must be tailored to individual DNA mutations, making it ineffective for conditions with numerous genetic variants. Zhang notes the impracticality of developing drugs for single patients, highlighting the need for methods that can insert complete healthy genes. This limitation has spurred development of tools capable of larger-scale genomic modifications.
3PASTE technique breakthrough
Harvard researchers Abudayyeh and Gootenberg developed PASTE, combining CRISPR with large serine integrases like Bxb1. This method can insert tens of thousands of DNA bases without breaking both strands. In monkey trials, it successfully replaced a hemophilia B-related gene in 50% of liver cells. However, PASTE's complexity - requiring multiple enzymes and delivery methods - presents challenges for widespread application beyond the liver.
4evoCAST's massive payloads
Columbia University's evoCAST system, developed by Sternberg and Liu, pushes insertion capacity to 15,000 DNA bases. Using CRISPR-associated transposases (CASTs), it targets specific genomic sites for therapeutic applications. The tradeoff comes in delivery complexity - some designs require six or seven proteins. Researchers are working to streamline components while maintaining the system's impressive DNA insertion capabilities.
5Recombineering advantages
Scripps Research's Shannon Miller explores bacterial recombineering for human cells. Her compact system fits within a single AAV genome's 1,500 base pair capacity. While currently more efficient in bacteria, improvements could make this simpler approach viable for human therapies. The method offers potential advantages in delivery efficiency compared to more complex multi-component systems.
6Retrotransposon delivery
R2 retrotransposons represent another approach, deliverable entirely as RNA in lipid nanoparticles. These can carry larger payloads than viral vectors, but require extensive re-engineering of DNA-binding domains for specific targeting. Most applications currently insert DNA into predetermined 'safe harbor' genomic regions to avoid harmful mutations, limiting their precision compared to other methods.
7Therapeutic potential
These technologies could revolutionize treatments like CAR T-cell therapy by enabling insertion of immune-stimulating proteins or tumor-activated genetic switches. For basic research, they allow creation of better disease models and synthetic chromosomes. However, each method's optimal use depends on factors like insertion size, target location, and cell type - no single solution fits all needs.
8Delivery challenges
All large-scale editing methods face significant delivery hurdles. PASTE requires both lipid nanoparticles and viral vectors. evoCAST's multiple proteins strain current delivery capabilities. While recombineering and retrotransposons offer simpler delivery options, they sacrifice precision or efficiency. Overcoming these delivery limitations represents the next major frontier in genomic medicine.
9The future of gene editing
The field has moved beyond CRISPR's limitations to develop specialized tools for different applications. As Miller notes, there's been 'an insane explosion of new technologies.' While none yet matches CRISPR's simplicity for small edits, these advances collectively expand what's possible in genomic medicine. The challenge now lies in refining delivery methods and demonstrating clinical efficacy across diverse therapeutic areas.
Original article: Nature — Beyond CRISPR: The New Generation of Genome Editors